Viewing Study NCT03715205


Ignite Creation Date: 2025-12-25 @ 3:30 AM
Ignite Modification Date: 2026-02-22 @ 2:36 AM
Study NCT ID: NCT03715205
Status: COMPLETED
Last Update Posted: 2025-08-29
First Post: 2018-10-19
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593)
Sponsor: Merck Sharp & Dohme LLC
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Carcinoma, Non-Small-Cell Lung View
None Melanoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None programmed cell death 1 (PD-1, PD1) View
None programmed cell death ligand 1 (PD-L1, PDL1) View
None programmed cell death ligand 2 (PD-L2, PDL2) View